If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Double-Boosted Protease-Inhibitor Therapy May Change Lipid Profiles for Patients With HIV: Presented at AIDS 2010 By Ed Susman VIENNA -- July 28, 2010 -- Double-boosted protease-inhibitor therapy may increase cholesterol and triglyceride levels in patients infected with HIV significantly more than treatment with just single-boosted protease regimens, researchers reported here at the 18th International AIDS Conference. "Double-boosted protease-inhibitor regimens appeared to play a bigger role in the elevation of lipids when compared with a single-boosted daily ritonavir dose and lopinavir," said Humberto Jimenez, PharmD, Rutgers University, Piscataway, New Jersey, speaking here at his poster presentation on July 21. Jimenez said that when clinicians attempted to use double-boosted regimens in this study -- such as atazanavir boosted with lopinavir and ritonavir or fosamprenavir boosted with saquinavir and ritonavir -- the effect on lipids was marked. Jimenez and his colleagues performed a retrospective chart review of 121 patients who had been treated at St. Michael's Medical Center, Newark, New Jersey, between March 2004 and December 2009, and had received only boosted protease-inhibitor therapy. The review excluded 44 patients due to missing data (most often lipid information). Total cholesterol among those on double-boosted regimens increased 21.5% compared with a 2.1% increase from baseline for patients on a single-boosted protease inhibitor (P = .05). Additionally, low-density lipoprotein cholesterol among those on double-boosted regimens increased 18.9% compared with a 6.3% decrease from baseline for patients on a single-boosted protease inhibitor (P = .033). The total cholesterol/high-density lipoprotein (HDL) cholesterol ratio among those on double-boosted regimens increased 0.45% compared with a 0.015% decrease from baseline for patients on a single-boosted protease inhibitor (P = .0495). Non-HDL cholesterol among those on double-boosted regimens increased 23.6% compared with a 0.9% decrease from baseline for patients on a single-boosted protease inhibitor (P = .038). Triglyceride levels also increased. Among those on double-boosted regimens triglycerides increased 29.9% compared with a 15.9% increase from baseline for patients on a single-boosted protease inhibitor. This difference did not achieve statistical significance. About 66% of the patients included in this study were men; the average age of the patients in the study was 47.8 years. About 36% of the patients were on double-boosted protease-inhibitor regimens. [Presentation title: Lipid Effects of Boost PI Therapy Alone in the Treatment of HIV. Abstract WEPE0119]
|
